Eton Pharmaceuticals Q3 revenue rises 158% to $57.9 million; 2026 revenue guidance raised
Eton Pharmaceuticals reported third quarter 2026 revenue of $57.9 million, up from $22.5 million a year earlier, and raised its 2026 revenue guidance to more than $175 million from more than $145 million. GAAP net income of $35.2 million, or $1.06 per diluted share, was boosted by a $12.9 million income tax benefit from releasing a valuation allowance, while non-GAAP diluted EPS was $0.50.
Key points
- Q3 2026 revenue was $57.9 million versus $22.5 million in Q3 2025, driven mainly by the addition of HEMANGEOL sales.
- Adjusted EBITDA was $28.5 million, or 49% of revenue, compared with $2.9 million, or 13%, a year earlier.
- 2026 revenue guidance was raised to more than $175 million from more than $145 million; Adjusted EBITDA margin guidance was raised to at least 40% from at least 35%.
- Cash and cash equivalents were $55.6 million as of September 30, 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.